ABUS Arbutus Biopharma Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1447028 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,142.6%
TTM net income YoY620.2%
TTM EPS YoY587.0%
Revenue 3-yr CAGR101.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin81.1%
Net margin121.2%
FCF margin—
EBITDA margin81.1%
Returns
ROE269.6%
ROA100.6%
ROIC (approx.)—
Asset turnover0.83x
Leverage & solvency
Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.40x
Interest coverage2,299.38x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $299,000 | $1.01M | $179.13M | $1.05M | $529,000 | $10.74M | $1.76M | $1.57M |
| R&D expense | $2.62M | $2.90M | $4.12M | $5.01M | $5.78M | $5.50M | $8.96M | $8.81M |
| SG&A expense | $7.96M | $3.87M | $5.89M | $3.69M | $3.04M | $3.33M | $5.83M | $4.71M |
| Operating income | -$10.49M | -$5.96M | $168.91M | -$5.29M | -$8.66M | $1.49M | -$25.70M | -$13.93M |
| Interest expense | $11,000 | $18,000 | $17,000 | $18,000 | $23,000 | $28,000 | $28,000 | $30,000 |
| Income tax | $0 | $0 | $0 | — | — | — | — | — |
| Net income | $59.12M | -$5.14M | $169.69M | -$3.76M | -$7.74M | $2.52M | -$24.53M | -$12.53M |
| EBITDA | -$10.48M | -$5.95M | $168.92M | -$5.28M | -$8.65M | $1.50M | -$25.37M | -$13.60M |
| EPS (basic) | 0.30 | -0.03 | 0.88 | — | -0.04 | 0.01 | -0.13 | — |
| EPS (diluted) | 0.30 | -0.03 | 0.87 | — | -0.04 | 0.01 | -0.13 | — |
| Weighted avg. shares (diluted) | 199.63M | 197.47M | 195.21M | — | 191.78M | 192.40M | 190.71M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $264.19M | $19.17M | $23.71M | $18.01M | $22.41M | $37.41M | $37.08M | $36.33M |
| Short-term investments | $73.30M | $73.45M | $71.52M | $73.46M | $71.29M | $60.68M | $75.63M | $86.29M |
| Receivables | $792,000 | $369,000 | $1.31M | $1.45M | $905,000 | $1.02M | $1.18M | $2.41M |
| Current assets | $339.57M | $273.88M | $277.01M | $94.46M | $97.44M | $103.12M | $116.81M | $127.32M |
| PP&E, net | $0 | $10,000 | $22,000 | $32,000 | $137,000 | $148,000 | $168,000 | $3.31M |
| Total assets | $339.70M | $274.02M | $277.16M | $94.62M | $97.71M | $103.27M | $117.01M | $131.71M |
| Current liabilities | $241.93M | $3.36M | $5.11M | $6.01M | $5.18M | $5.02M | $19.43M | $15.62M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $253.95M | $15.29M | $16.99M | $18.04M | $20.31M | $20.29M | $37.85M | $34.34M |
| Shareholders' equity | $85.75M | $258.73M | $260.18M | $76.58M | $77.40M | $82.98M | $79.16M | $97.37M |
| Net debt | -$264.19M | -$19.17M | -$23.71M | -$18.01M | -$22.41M | -$37.41M | -$37.08M | -$36.33M |
| Shares outstanding | 199.28M | 197.63M | 196.95M | 192.53M | 191.95M | 191.64M | 191.48M | 189.96M |
| Cash flow statement | ||||||||
| Operating cash flow | $239.81M | -$6.02M | -$8.11M | -$4.68M | -$5.82M | -$15.75M | -$13.39M | -$10.31M |
| Capital expenditure | — | — | — | $0 | $0 | $0 | $0 | $86,000 |
| Free cash flow | — | — | — | -$4.68M | -$5.82M | -$15.75M | -$13.39M | -$10.40M |
| Investing cash flow | $504,000 | -$1.66M | $2.20M | -$1.36M | -$10.02M | $15.61M | $11.35M | $13.41M |
| Financing cash flow | $4.71M | $3.15M | $11.62M | $1.64M | $844,000 | $453,000 | $2.78M | $1.42M |
| Depreciation & amortization | $10,000 | $11,000 | $11,000 | $11,000 | $11,000 | $11,000 | $330,000 | $333,000 |
| Stock-based compensation | $1.16M | $1.59M | $1.36M | $1.26M | $1.20M | $764,000 | $3.56M | $1.63M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.